Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 440 participants.
Also called NCT03072121
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 440 participants
- Registry
-
NCT03072121
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT03072121. Randomized; double masking; primary purpose treatment. Start 2017-06 (anticipated); primary completion 2018-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization
- Intervention (Drug)
- Shexiang Baoxin pill
- Intervention (Drug)
- SBP placebo
- Intervention (Drug)
- Aspirin Enteric-coated Tablets
- Intervention (Drug)
- Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
- Intervention (Drug)
- Atorvastatin Calcium
- Intervention (Drug)
- Isosorbide Mononitrate Tab 20 MG
- Intervention (Drug)
- Metoprolol Tartrate Tab 25 MG
- Intervention (Drug)
- Trimetazidine Dihydrochloride Tablets
- Lead sponsor
- Jun Li
- Collaborator
- Shanghai Hutchison Pharmaceuticals Limited
Record details
- Record id
cardio:ct-nct03072121- Content hash
0ab60d2d2e32bf9447f354ae7f85a619c75387bf36d6ab9e609ccc40f01a898c